Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Want to cut your energy bills? Here’s how five experts are doing it 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Geneva, Switzerland and Boston, MA - 31 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder, Tim ADAMS, CFO, and Mario CORSO, Senior Director Investor Relations will attend the Jefferies Healthcare Conference. Management will be presenting on Thursday June 8th at 08:30 a.m. and will be hosting one-on-one meetings at the Grand Hyatt Hotel in New York City.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Company Contact:
CEO Office contact
Delphine Renaud
[email protected]
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/70181aa5-664e-4bd9-a30f-7dcaa32de878
